Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Thoracic 3

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 1Carcinoma, Bronchogenic 1

Interventions

Carboplatin 98Pemetrexed 70pembrolizumab 68Cisplatin 59Paclitaxel 54Docetaxel 45Gemcitabine 37Erlotinib Hydrochloride 24Nivolumab 23osimertinib 17Bevacizumab 17durvalumab 14Cetuximab 13130-nm albumin-bound paclitaxel 13Gefitinib 11Etoposide 11Drug Therapy 11Ipilimumab 9Injections 9Albumin-Bound Paclitaxel 9Vinorelbine 8Radiotherapy 8motexafin gadolinium 7capmatinib 7atezolizumab 7epacadostat 6Taxes 6Cyclophosphamide 6vandetanib 5entinostat 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Lung Neoplasms × belagenpumatucel L × Clear all
NCT00676507 2015-05-08

STOP

NovaRx Corporation

Phase 3 Completed
532 enrolled
Thoracic

Lung Neoplasms

NCT01279798 2011-03-01

Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)

NovaRx Corporation

No longer available
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01058785 2010-07-29

Phase II Study of Lucanixâ„¢ in Patients With Stages II-IV Non-Small Cell Lung Cancer

NovaRx Corporation

Phase 2 Completed
75 enrolled
Thoracic

Carcinoma, Bronchogenic, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡